Home > Products > Anticancer/Antitumor/Antineoplastic > Ethyl 2- 3-formyl-4-isobutoxyphenyl CAS 161798-03-4

Ethyl 2- 3-formyl-4-isobutoxyphenyl CAS 161798-03-4

    Incoterm: FOB,CIF
    Min. Order: 1 Bag/Bags
    Delivery Time: 1 Days
Basic Info

Model No.: jf003-02

Function: Respiratory System Agents, Anesthetic and Adjuvant, Antineoplastic

Certification: FDA

Grade Standard: Medicine Grade

Type: Chemical Reagent

State: Solid

Volatile: Not Volatile

Assay: 99%

Additional Info

Packaging: bag

Productivity: 2000kg

Brand: Jianfeng

Transportation: Land

Place of Origin: China

Supply Ability: 2045kg

Certificate: ISO

HS Code: 29349990.06

Port: Shanghai

Product Description

Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications).Product Name: Imatinib Mesilate

CAS NO: 220127-57-1

Standard: Enterprise Standard

Molecular Formula: C30H35N7O4S

Molecular Weight : 589.71

Description: White crystal or crystalline powder

Package :25KG/drums

Chemical names, synonyms:

4-[(4-methyl-1-piperazinyl)methyl]-n-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide monomethanesulfonate, STI-571, IMATINIB BASE(IMA-3), Imatinib (STI-571) Mesylate

Minimum purity: 99%

161798 03 4


White to off-white Crystalline Powder

Identification By IR

IR spectrum of the sample should concordant to the standard spectrum.


Soluble in Water


NMT 0.5% w/w

Related substance


Single Max. Imp : NMT 0.1 %

Total Max Imp : NMT 1.0 %

Assay (By HPLC)

NMT 98.0% And NLT 102 %


NMT 0.5%

Heavy metals

NMT 0.5%

Thermo gram


Imatinib Mesylate is a targeted therapy. Imatinib Mesylate is classified as a signal transduction inhibitor - protein-tyrosine kinase inhibitor.

A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.

Imatinib mesylate (also called Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia.

As an inhibitor of PDGFR, imatinib mesylate appears to have utility in the treatment of a variety of dermatological diseases. Imatinib has been reported to be an effective treatment for FIP1L1-PDGFRalpha+ mast cell disease, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans.

Looking for ideal FebuxostatI Intermediate Price Manufacturer & supplier ? We have a wide selection at great prices to help you get creative. All the FebuxostatI Effects 161798-03-4 are quality guaranteed. We are China Origin Factory of FebuxostatI Intermediate Dose. If you have any question, please feel free to contact us.

Product Categories : Anticancer/Antitumor/Antineoplastic

Email to this supplier
  • *Subject:
  • *Messages:
    Your message must be between 20-8000 characters
Communicate with Supplier?Supplier
Mr. Vid Mr. Mr. Vid
What can I do for you?
Contact Supplier